Stay updated with breaking news from Pharm services. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Edinburgh Innovations | Scotland's Life Sciences Awards 2024: five… ed.ac.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from ed.ac.uk Daily Mail and Mail on Sunday newspapers.
Press release content from Globe Newswire. The AP news staff was not involved in its creation. Orchard Therapeutics Secures Partnerships to Broaden Access to LibmeldyTM for Eligible Patients . Orchard Therapeutics (Europe) LimitedJanuary 19, 2021 GMT BOSTON and LONDON, Jan. 19, 2021 (GLOBE NEWSWIRE) Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced plans to extend the company’s commercial reach in the Middle East and Turkey through exclusive agreements with GenPharm Services and GEN, two leading regional specialty pharmaceutical companies with extensive experience in rare genetic disease. GenPharm and GEN will collaborate with Orchard to facilitate access to treatment with Libmeldy in European-based qualified treatment centers for eligible patients living in the Middle East and Turkey. ....
ex vivo using a lentiviral vector encoding the human arylsulfatase-A ( ARSA) gene), also known as OTL-200, has been approved by the European Commission for the treatment of MLD in eligible early-onset patients characterized by biallelic mutations in the ARSA gene leading to a reduction of the ARSA enzymatic activity in children with i) late infantile or early juvenile forms, without clinical manifestations of the disease, or ii) the early juvenile form, with early clinical manifestations of the disease, who still have the ability to walk independently and before the onset of cognitive decline. Libmeldy is the first therapy approved for eligible patients with early-onset MLD. ....